World ADC on June 10-12, 2025 in Seoul, Republic of Korea

Following Isen's groundbreaking $1B+ ADC deal with China-based Foreseen Biotechnology, the rapid rise of new companies, billions of dollars in investments, and a surge in partnerships involving Asian firms continue to capture the world’s attention. All eyes are now focused on the clinical validation of the next big leap in ADC technologies.

In response to this momentum, the 4th World ADC Asia Summit is back, offering the most comprehensive platform for Asia’s rapidly growing ADC community. This summit brings together cutting-edge innovators from Asia and the expertise of the West to chart a path to ADC success across the region.

This year, we’re introducing 3 dynamic tracks covering discovery, preclinical, clinical, and CMC, alongside exclusive seminar days focusing on ADC fundamentals and Bispecific ADCs. Whether you're just starting out or a seasoned expert, the program offers something for professionals at every level.

Don’t miss this opportunity to gain a complete view of the ADC landscape in Asia. You’ll have access to insightful sessions on novel design trends, emerging clinical data, and strategic partnering and licensing decisions. Plus, connect with over 60+ industry-leading speakers from top companies such as AstraZeneca, Daiichi Sankyo, leading Asian ADC biotechs, innovative start-ups, and top-tier ADC service providers from around the globe.

URLs:

Website: https://go.evvnt.com/2915095-0?pid=10008

Brochure: https://go.evvnt.com/2915095-3?pid=10008

Time: 9:30 AM - 4:45 PM

Prices:

Drug Developer Pricing Conference + Pre-Conference Seminar Day: USD 2327.00,

Drug Developer Pricing Conference Only: USD 1749.00,

Academic Pricing Conference + Pre-Conference Seminar Day: USD 2127.00,

Academic Pricing Conference Only: USD 1549.00,

Service Provider Conference + Pre-Conference Seminar Day: USD 5197.00,

Service Provider Conference Only: USD 3799.00

Speakers: Alain Beck, Senior Director, Biologics CMC, Pierre Fabre, Amy Que, Chief Technology Officer, GeneQuantum, Atsuko Takatsuka, Discovery Research, Daiichi Sankyo, Byoung Chul Lee, Chief Executive Officer, Kanaph Therapeutics, Dongzhou Liu, Chief Scientific Officer, Huadong Medicine, Doo Young Jung, Chief Executive Officer, Pinotbio, George Badescu, Chief Business Officer, Heidelberg Pharma, Gerold Meinhardt, Vice President of Asset and Portfolio Management, Daiichi Sankyo, Gilles Gallant, Chief Development Officer, Mythic Therapeutics, Haiqing Hua, Head of Drug Discovery and Senior Vice President, Duality Biologics, Heidi Wang, Chief Executive Officer, OBI Pharma Inc., Hsing-Mao Chu, Vice President of Research and Development, Immunwork Inc, Jinwon Jung, Senior Director of Protein Engineering, ABL Bio, John L. Xu, Executive Vice President, Pharmaceutical R AND D, GeneScience Pharmaceutical Co, John Luk, Founder, Arbele Bio, Markus Schick, Director and Head of Computational Pathology and Biomarker Development, AstraZeneca, Martha Li, Companion Diagnostic Strategy Lead, Abbvie, Nam-Gu Her, Chief Executive Officer, Aimed Bio Inc., Paul Song, Chief Scientific Officer, Genequantum Healthcare, Pooja Desai, Director of Biotherapeutics CMC, Exelixis, Inc., Robert Huang, Founder and Chief Executive Officer, Coherent Biopharma, Rongliang Lou, Executive Director, Innovent Bio, Seb Caille, Scientific Director of Process Development, Amgen Inc., Shu-Ichi Hashimoto, Head of Drug Discovery Research, Chiome Bioscience Inc., Sijie Lu, Head of Clinical Pharmacology, Roche, Simon Shih-Hsien Chuang, Chief Executive Officer, HoneyBear Biosciences, Shumin (Sam) Liu, Chief Executive Officer, Shenzhen Enduring Biotech, SJ Lee, Chief Executive Officer, Orum Therapeutics, Soo Min Lee, Managing Director, Samjin Pharmaceutical, Wei-Han Lee, Director of Analytics, OBI Pharma Inc., Wenbin Lu, Senior Director, Daiichi Sankyo, Yu Zhang, CMC Director, Duality Biologics, Yu-Shin Hsu, Research Analyst, Beacon by Hanson Wade, Yue Huang, Ex Regulatory Affairs, Chemistry, Manufacturing and Controls Manager, Daiichi Sankyo, Zou Bin, Founder and Chief Executive Officer, Axcynsis Therapeutics